Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology-assisted reproduction technology

Gynecological Endocrinology

Volumn 31, Issue 6, 2015, Pages 441-446

  Bevilacqua, Arturo ^a   Carlomagno, Gianfranco ^b   Gerli, Sandro ^c   Montanino Oliva, Mario ^d   Devroey, Paul ^e   Lanzone, Antonio ^f   Soulange, Christophe ^g   Facchinetti, Fabio ^h   Carlo Di Renzo, Gian ^c,i   Bizzarri, Mariano ^a   Hod, Moshe ^j   Cavalli, Pietro ^k   D'Anna, Rosario ^l   Benvenga, Salvatore ^m   Chiu, Tony T ⁿ   Kamenov, Zdravko A ^o  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LoLi Pharma RandD Department   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Clinica Villa Mafalda   (Italy)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITÉ DE LYON   (France)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ PREIS School   (Italy)

^j RABIN MEDICAL CENTER   (Israel)

^k CREMONA HOSPITAL   (Italy)

^l UNIVERSITY OF MESSINA   (Italy)

^m UNIVERSITY OF MESSINA   (Italy)

ⁿ Hong Kong Academy of Medicine   (Hong Kong)

^o UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

more..

Author keywords

Infertility; Ovary; Ovulation induction; Polycystic ovary syndrome; Pregnancy

Indexed keywords

D CHIRO INOSITOL; INOSITOL; INOSITOL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CONSENSUS; EMBRYO DEVELOPMENT; FERTILIZATION IN VITRO; GLUCOSE TRANSPORT; HUMAN; INFERTILITY THERAPY; MENSTRUAL CYCLE; OOCYTE DEVELOPMENT; OOCYTE MATURATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REPRODUCTION; SPERMATOZOON; STEREOISOMERISM; ANIMAL; FEMALE; MALE; OOCYTE; ORGANIZATION; PHYSIOLOGY; STANDARDS;

ANIMALS; CONGRESSES AS TOPIC; CONSENSUS; FEMALE; HUMANS; INOSITOL; MALE; OOCYTES; REPRODUCTIVE TECHNIQUES, ASSISTED; SPERMATOZOA;

EID: 84938076647     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2015.1006616     Document Type: Article

References (71)

1. van Loendersloot LL, van Wely M, Limpens J, et al. Predictive factors in in vitro fertilization (IVF): a systematic review and metaanalysis. Hum Reprod Update 2010;16:577-89.
2. Rienzi L, Vajta G, Ubaldi F. Predictive value of oocyte morphology in human IVF: a systematic review of the literature. Hum Reprod Update 2010;17:34-45.
3. Revelli A, Delle Piane L, Casano S, et al. Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. Reprod Biol Endocrinol 2009;7:40.
4. Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591-6.
5. Pal L, Jindal S, Witt BR, Santoro N. Less is more. . . Increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth following IVF. Fertil Steril 2008; 89:1694-701.
6. Ciotta L, Stracquadanio M, Pagano I, et al. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 2011;15:509-14.
7. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750-4.
8. Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol 2011;27:857-61.
9. Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than Dchiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011;15:452-7.
10. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiroinositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 2013;288:1405-11.
11. Lisi F, Carfagna P, Oliva MM, et al. Pretreatment with myo-inositol in non-polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 2012;10:52.
12. Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myoinositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci 2010;14:555-61.
13. Chattopadhayay R, Ganesh A, Samanta J, et al. Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. Gynecol Obstet Invest 2010;69:197-202.
14. Berker B, Kaya C, Aytac R, Satiroglu H. Homocysteine concentrations in follicular fluid are associated with poor oocyte and embryo qualities in polycystic ovary syndrome patients undergoing assisted reproduction. Hum Reprod 2009;24:2293-302.
15. Condorelli RA, La Vignera S, Bellanca S, et al. Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology 2012;79:1290-5.
16. Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effects of myoinositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003;18:408-16.
17. Holm P, Booth PJ, Schmidt MH, et al. High bovine blastocyst development in a static in vitro production system using SOFaa medium supplemented with sodium citrate and myo-inositol with or without serum-proteins. Theriogenology 1999;52:683-700.
18. Warner SM, Conlon FV, Kane MT. Inositol transport in preimplantation rabbit embryos: effects of embryo stage, sodium, osmolality and metabolic inhibitors. Reproduction 2003;125:479-93.
19. Colazingari S, Fiorenza MT, Carlomagno G, et al. Improvement of mouse embryo quality by myo-inositol supplementation of IVF media. J Assist Reprod Genet 2014;31:463-9.
20. Huang LC, Fonteles MC, Houston DB, et al. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 1993; 132:652-7.
21. Sun TH, Heimark DB, Nguygen T, et al. Both myo-inositol to chiroinositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002;293:1092-8.
22. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006;443:651-7.
23. Downes CP. The cellular functions of myo-inositol. Biochem Soc Trans 1989;17:259-68.
24. Downes CP, Macphee CH. myo-inositol metabolites as cellular signals. Eur J Biochem 1990;193:1-18.
25. Beemster P, Groenen P, Steegers-Theunissen R. Involvement of inositol in reproduction. Nutr Rev 2002;60:80-7.
26. Quirk Jr JG, Bleasdale JE. Myo-inositol homeostasis in the human fetus. Obstet Gynecol 1983;62:41-4.
27. Greene NDE, Copp AJ. Inositol prevents folate resistant neural tube defects in the mouse. Nat Med 1997;3:60-6.
28. Cavalli P, Copp AJ. Inositol and folate resistant neural tube defects. J Med Genet 2002;39:E5.
29. Lewin LM, Yannai Y, Melmed S, Weiss M. Myo-inositol in the reproductive tract of the female rat. Int J Biochem 1982;14:147-50.
30. Chiu TT, Tam PP. A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 1992;9:524-30.
31. Zacche MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508-13.
32. Matsuda M, Tsutsumi K, Kanematsu T, et al. Involvement of phospholipase C-related inactive protein in the mouse reproductive system through the regulation of gonadotropin levels. Biol Reprod 2009;81:681-9.
33. Goud PT, Goud AP, Van Oostveldt P, Dhont M. Presence and dynamic redistribution of type I inositol 1,4,5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions. Mol Hum Reprod 1999;5: 441-51.
34. Lowther KM, Weitzman VN, Maier D, Mehlmann LM. Maturation, fertilization, and the structure and function of the endoplasmic reticulum in cryopreserved mouse oocytes. Biol Reprod 2009;81: 147-54.
35. Kwon HM, Yamauchi A, Uchida S, et al. Cloning of the cDNA for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. J Biol Chem 1992;267:6297-301.
36. Higgins BD, Kane MT. Inositol transport in mouse oocytes and preimplantation embryos: effects of mouse strain, embryo stage, sodium and the hexose transport inhibitor, phloridzin. Reproduction 2003;125:111-18.
37. Kane MT, Norris M, Harrison RAP. Uptake and incorporation of inositol by preimplantation mouse embryos. J Reprod Fertil 1992; 96:617-25.
38. Ajduk A, Ciemerych MA, Nixon V, et al. Fertilization differently affects the levels of cyclin B1 and M-phase promoting factor activity in maturing and metaphase II mouse oocytes. Reproduction 2008; 136:741-52.
39. Stachecki JJ, Armant DR. Transient release of calcium from inositol 1,4,5-trisphosphate-specific stores regulates mouse preimplantation development. Development 1996;122:2485-96.
40. Homburg R. Polycystic ovary syndrome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996;11: 29-39.
41. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999;48:167-72.
42. Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81:114-9.
43. Nestler JE, Strauss 3rd JF. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am 1991;20:807-23.
44. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012;97:18-22.
45. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009; 13:105-10.
46. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700-3.
47. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347-54.
48. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314-20.
49. Iuorno MJ, Jacubowicz DJ, Baillargeon JP, et al. Effect of D-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417-23.
50. Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:920-4.
51. Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to D-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 2014;21:854-8. [Epub ahead of print]. PubMed PMID:24501149.
52. Eisenberg Jr F, Bolden AH. Reproductive tract as site of synthesis and secretion of inositol in the male rat. Nature 1964;202: 599-600.
53. Chauvin TR, Griswold MD. Characterization of the expression and regulation of genes necessary for myo-inositol biosynthesis and transport in the seminiferous epithelium. Biol Reprod 2004;70: 744-51.
54. Hinton BT, White RW, Setchell BP. Concentrations of myo-inositol in the luminal fluid of the mammalian testis and epididymis. J Reprod Fertil 1980;58:395-9.
55. Cryns K, Shamir A, Van Acker N, et al. IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacol 2008;33:674-84.
56. Martinez-Heredia J, de Mateo S, Vidal-Taboada JM, et al. Identification of proteomic differences in asthenozoospermic sperm samples. Hum Reprod 2008;23:783-91.
57. Colone M, Marelli G, Unfer V, et al. Inositol activity in oligoasthenoteratospermia-an in vitro study. Eur Rev Med Pharmacol Sci 2010;14:891-6.
58. Condorelli RA, La Vignera S, Di Bari F, et al. Effects of myoinositol on sperm mitochondrial function in-vitro. Eur Rev Med Pharmacol Sci 2011;15:129-34.
59. Marchetti C, Jouy N, Leroy-Martin B, et al. Comparison of four fluorochromes for the detection of the inner mitochondrial membrane potential in human spermatozoa and their correlation with sperm motility. Hum Reprod 2004;19:2267-76.
60. Marchetti P, Ballot C, Jouy N, et al. Influence of mitochondrial membrane potential of spermatozoa on in vitro fertilisation outcome. Andrologia 2012;44:136-41.
61. Isabella R, Raffone E. Does ovary need D-chiro-inositol? J Ovarian Res 2012;5:14.
62. Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositol phosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390-7.
63. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3:47-60.
64. Ma X, Fan L, Meng Y, et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 2007;13:527-35.
65. Arya BK, Haq AU, Chaudhury K. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med Hypotheses 2012;78:475-8.
66. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95:2515-6.
67. Nordio M, Proietti E. The combined therapy with myo-inositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16:575-81.
68. Larner J, Huang LC, Tang G, et al. Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol 1988;53:965-71.
69. Majumder AL, Biswas BB. Biology of inositols and phoshoinositides. Subcellular Biochemistry. The Netherlands; Springer; 2006:2039.
70. Chaudhary K, Babu KN, Joshi VN, et al. NMR-based metabolomics reveals differently expressed metabolites in follicular fluid of PCOS women: potential biomarkers for good quality oocyte? Hum Reprod 2011;26:i226-46.
71. Heimark D1, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 2014;61:111-17.